S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|ChemoCentryx Announces GlaxoSmithKline's Release of Top-Line Results From the SHIELD-1 Phase III Study of Vercirnon ()|
|ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology (2014/3/27)|
|ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013 (2014/3/13)|
|ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis (2013/12/3)|
|ChemoCentryx to Regain Global Rights for Vercirnon From GlaxoSmithKline ()|
|ChemoCentryx Announces Top-Line Interim Results for CCX140, an Orally Administered CCR2 Inhibitor, in an Ongoing 52 Week Phase II Trial in Patients With Diabetic Nephropathy ()|
|ChemoCentryx Announces Financial Results for the Quarter Ended June 30, 2013 ()|
|ChemoCentryx Announces Financial Results for the Quarter Ended September 30, 2013 ()|
|ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014 (2014/3/3)|
|ChemoCentryx, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 12, 2013 (2013/8/1)|
Click above to view more mutual fund data and stats for ccxi - Chemocentryx Inc.